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Deletions ranging from 100 Kb to 1 Mb—too small to be detected under the microscope—may still involve dozens
of genes, thus causing microdeletion syndromes. The vast majority of these syndromes are caused by haploinsuf-
ficiency of one or several genes and are transmitted as dominant traits. We identified seven patients originating
from an extended family and presenting with a unique syndrome, inherited in a recessive mode, consisting of
cystinuria, neonatal seizures, hypotonia, severe somatic and developmental delay, facial dysmorphism, and lactic
acidemia. Reduced activity of all the respiratory chain enzymatic complexes that are encoded in the mitochondria
was found in muscle biopsy specimens of the patients examined. The molecular basis of this disorder is a homozygous
deletion of 179,311 bp on chromosome 2p16, which includes the type I cystinuria gene (SLC3A1), the protein
phosphatase 2Cb gene (PP2Cb), an unidentified gene (KIAA0436), and several expressed sequence tags. The extent
of the deletion suggests that this unique syndrome is related to the complete absence of these genes’ products, one
of which may be essential for the synthesis of mitochondrial encoded proteins.
The vast majority of syndromes associated with dele-
tions of 100 Kb to 1Mb are caused by haploinsufficiency
of one or several genes and are transmitted as dominant
traits. Homozygous deletions are usually lethal and, in
the heterozygote state, only a few dosage-sensitive genes
cause the phenotype. A recessive contiguous gene dele-
tion has been reported only once for a homozygous 122-
kb deletion of 11p14-15, associated with profound, con-
genital sensorineural deafness, severe hyperinsulinemic
hypoglycemia, enteropathy, and renal tubular dysfunc-
tion. This phenotype could be explained by the under-
lying absence of more than half of the ABCC8 gene
(MIM 600509) and partial deletion of the USHER syn-
drome type IC gene (USH1C [MIM 276904]; Bitner-
Glindzicz et al. 2000).
Cystinuria (MIM 220100) is a relatively common au-
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tosomal recessive disorder of the transport of cystine and
dibasic amino acids through the epithelial cells of the
renal tubuli and the intestinal brush border (Segal and
Their 1995). The clinical manifestations are predomi-
nantly renal and are attributed to cystine calculi. The
frequency of neurological deficits is comparable to that
in the general population (Gold et al. 1977). Mutations
in either the light or the heavy chain of the dibasic amino
acids and cystine transport system (bo,AT) have been
identified in cystinuric patients (Calonge et al. 1994;
International Cystinuria Consortium 1999). The heavy
chain, rBAT, is encoded by the SLC3A1 gene (MIM
104614), which resides on chromosome 2 (Pras et al.
1994) and is linked by a disulfide bond to the catalytic
light chain, (bo,AT), which is encoded by the SLC7A9
gene (MIM 604144) on chromosome 19 (Bisceglia et al.
1997).
Seven patients (4 male and 3 female) from three nu-
clear families of a small Bedouin clan (fig. 1a) partici-
pated in this study, after informed consent was obtained.
They were followed until the oldest subject was aged 16
years. Their medical records were carefully reviewed,
and details of their somatic growth, psychomotor de-
velopment, clinical course, hospitalizations, and labo-
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Figure 1 a, Pedigree of the extended Bedouin family with seven children affected with cystinuria, neonatal seizures, hypotonia, severe
somatic and developmental delay, facial dysmorphism, mitochondrial disease, and lactic acidemia. Family members whose symbols are numbered
and marked with a small horizontal line were available for the DNA studies. b, Linkage analysis to markers D2S2306 and D2S177, showing
one homozygous allele in all patients. The pedigree members’ symbols, marked as in a, are arranged above each gel lane. Markers D2S119
and D2S2220 showed similar patterns.
ratory results were recorded. Their parents and siblings
were interviewed and underwent complete physical ex-
amination and urine amino acid analysis.
Decreased fetal movements were reported in two pa-
tients. All the patients were born at term, with normal
growth parameters. Nonetheless, all fed poorly and ex-
hibited linear growth impairment and severe failure to
thrive. At birth, all patients had generalized severe axial
hypotonia and a weak cry, and five suffered from neo-
natal seizures. The postnatal global development was
delayed; muscle tone improved after 2 years of age, but
walking was achieved only at 5–7 years of age. Despite
intact hearing, speech was incomprehensible, and mod-
erate to severe mental retardation was evident in all the
patients. Brain CT scan, which was performed in four
patients, was normal in three patients and disclosedmild
dilatation of the right ventricle, due to neonatal hem-
orrhage, in one patient. Dysmorphic facies, including
frontal bossing, almond-shaped eyes, long eyelashes, de-
pressed nasal bridge, and large, posteriorly rotated ears,
were noted in all patients. Visceral organs were of nor-
mal size in all patients. Growth failure continued into
childhood, and the oldest patients, a 16-year-old boy
and a 13-year-old girl, do not yet show any pubertal
signs.
Renal and/or bladder cystine calculi were detected in
all patients as early as 9 months of age, and excretion
of arginine, lysine, ornithine, and cystine in urine was
markedly increased; response to urine alkalinization and
penicillamine was inconsistent. Transient neonatal hy-
pocalcemia and hypoglycemia were noted in four and
two patients, respectively. Serum lactate level was ele-
vated in four of the seven patients, and the urinary or-
ganic acids analysis suggested an impairment of mito-
chondrial fatty acids oxidation in one patient.
In the mitochondrial enriched fraction of the muscle
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of one patient (fig. 1a; patient V10), the enzymatic ac-
tivity of mitochondrial respiratory chain (MRC) com-
plex IIII was 27%; complex IIIII, 45%; complex IV,
39%; and complex V, 68% of the control mean, nor-
malized for citrate synthase activity. Only complex II,
which does not contain any mitochondrial encoded sub-
unit, had normal activity (119%). In the mitochondrial
enriched fraction of the muscle of a second patient (fig.
1a; patient IV5), the activity of MRC complex IIII
activity was 55%; complex IV, 27%; and complex V,
36% of the control mean, normalized for citrate syn-
thase activity. The nuclear encoded complex II activity
was normal (90%). In a third patient (fig. 1a; patient
V3) whose muscle was subjected to histochemical anal-
ysis only, ragged red fibers were demonstrated. These
findings were compatible with an MRC defect. The ratio
of the mitochondrial DNA (mtDNA) to nuclear DNA
in muscle mitochondria of the first patient was 30% of
the control mean.
Linkage to the SLC7A9 gene (Bisceglia et al. 1997) was
excluded by the finding of four recombination eventswith
two adjacent genetic markers (D19S433 and D19S245).
Marker information and PCR amplification conditions
were obtained from the Genome Database. Visualization
of the PCR products was done by the addition of a[32P]-
dCTP, as detailed in Parvari et al. (1998). Linkage analysis
to the SLC3A1 gene on chromosome 2p16 (Pras et al.
1994), using the polymorphic markers D2S177,
D2S2306, D2S2220, and D2S119, revealed homozy-
gosity for the same allele in all patients; this was not
present in any of the healthy relatives tested (fig. 1b,
which presents results forD2S177 andD2S2306; results
for D2S2220 and D2S119 are not shown.) Siblings ap-
peared homozygous where one parent was not infor-
mative, but this homozygosity was not observed for the
other marker; for example, at marker D2S2306, V8 and
V9 are homozygous because their father, IV4, was ho-
mozygous. This result suggests that this locus is involved
with the disease in this family. PCR amplification of the
SLC3A1 exons was performed according to Pras et al.
(1996). Repeated failures to amplify the 10 exons of the
SLC3A1 gene with the patients’ DNA, along with nor-
mal amplification products with the parents’ DNA, in-
dicated that the SLC3A1 gene is deleted (fig. 2a). The
presence in patients’ DNA of multiple adjacent genes
extracted from the database of GeneMap and the Unified
Database for Human Genome Mapping was verified by
PCR amplification. These included malate dehydroge-
nase (MDH1 [MIM 154200]); butyrate response factor
2 (BRF2); 3-hydroxanthranilic acid dioxygenase
(HAAO); Cdc42 effector protein 3 (CEP3); splicing fac-
tor arginine/serine-rich 7 (SFRS7 [MIM 600572]); gua-
nine nucleotide exchanger factor (SOS1); glutamine
cyclotransferase (QPCT); ATPase, H transporting, ly-
sosomal (Vacuolar proton pump) 9kD (ATP6H [MIM
603931]); and cytochrome c oxidase subunit VII–related
protein (COX7RP). Specifically, the mitochondrial
translation initiation factor 2 (MTIF2 [MIM 603766])
and the mitochondrial deoxyguanosine kinase
(DGUOK [MIM 601465]) genes were also not included
in the deletion; furthermore, both were normally tran-
scribed, as determined by RT-PCR with patients’ lym-
phoblastoid RNA (not shown), thus excluding their in-
volvement in the MRC defect. However, the possibility
remains that compromised transcription of other genes
outside the region may be the cause of the observed
phenotype.
To estimate the size of the deletion, we used the se-
quence available in GenBank to design primers for PCR
amplification on both sides of the SLC3A1 gene. Se-
quence-tagged sites (STSs) were designed on the basis
of the genomic region available at GenBank after
RepeatMasker and BLAST were used, against the nr and
htgs databases, to confirm their unique sequences (avail-
able upon request). Absence of amplification after mul-
tiple attempts, in the presence of good amplification of
control samples, was taken as evidence that the sequence
of at least one of the primers was within the deletion.
We then designed primers to amplify across the deletion
(fig. 3a; primers “a,” located on the left side of the de-
letion [5′-AGCTAGAAGAAACTGGGGAAG-3′] and
“b,” located on the right side of the deletion [5′-AATGC-
TAATACCACTTGGGTC-3′]). Sequencing across the
deletion was done on the PCR product of primers a and
b, which define the deletion borders. The PCR product
was purified using the QIAquick kit (Qiagen), and se-
quencing was performed on an ABI 3700 machine, using
the fluorescent dideoxy termination method. The result
of the sequence indicated that the size of the deletion is
179,311 bp; either side of the deletion could contribute
four nucleotides (CCTT) at the joining site, since they
are present in both (fig. 3b). The deletion could have
been caused by an excision transposition event through
alignment of two Alu elements on clone RP11-559M23,
whose ends reside 806 bp and 3,343 bp from the edge,
to an Alu element on clone RP11-559M23, whose end
resides 1,020 bp from the edge. A multiplex PCR re-
action was designed using primers a and b, located on
the margins of the deletion breakpoint, and primer “c”
(5′-TAACTGGGTGGTGATGAGGAG-3′), located
within the deleted region, and identifies the presence of
the wild-type sequence (fig. 3a). This multiplex reaction
confirmed that all eight parents were heterozygous and
that all patients were homozygous for the deleted allele
(fig. 2b).
BLAST search of the deleted sequence against the nr
and dbEST databases revealed the presence of three
genes and 20 expressed sequence tags (ESTs) (fig. 3a).
These three genes—SLC3A1, protein phosphatase 2Cb
(PP2Cb [MIM 603770]; Marley et al. 1998), and
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Figure 2 a, Results of PCR amplifications of the SLC3A1 exons (1–10) and an unrelated gene (N.R.). The patients’ DNA (V10 and V15
in fig. 1a) failed to amplify the SLC3A1 exons, whereas good amplification was observed for DNA from a parent (IV1 in fig. 1a) and a control.
The quality of the patients’ DNA was assessed by its ability to amplify an unrelated gene. A p affected, P p parent, C p unrelated control
individual, and M p molecular weight marker X of Amersham. b, Multiplex PCR assay defining the deletion borders. Affected children are
indicated by blackened symbols. The PCR reaction included primers a, b, and c, as indicated in fig. 3a. Primers’ concentrations were 1 mM
for primers b and c and 0.5 mM for primer a; annealing temperature was 57C. The 439-bp product was obtained only if a normal allele was
present; the 376-bp product was obtained only if a deletion allele was present. All parents are therefore heterozygotes for the deletion and the
wild-type allele. Mp the molecular weight marker X of Amersham. c, Results of RT-PCR from lymphoblastoid RNA from an affected individual
(A; V10 in fig. 1a) compared with control (C) of the SLC3A1, PP2Cb, and KIAA0436 genes. None of these transcripts are PCR-amplified in
the affected individual. The actin gene was included to assess RNA quality. Primers for the PCR were selected on different exons, to avoid
amplification from residual DNA in the RNA preparation.
KIAA0436 (Ishikawa et al. 1997)—were not transcribed
in the patients (fig. 2c). RNA was extracted, using Trizol
(Gibco), from lymphoblastoid cell lines of two patients.
RT-PCR amplification of SLC3A1, PP2Cb, and
KIAA0436 was performed in one step, using the Ready
to Go kit (Amersham Pharmacia). For better visualiza-
tion of the KIAA0436 product, the RT-PCR was PCR-
reamplified. Primers used were as follows: for SLC3A1,
forward: 5′-gcaaatctcaatgaaagctatg-3′, and reverse: 5′-
cttgatataacttcaaagccg-3′; forKIAA0436, forward: 5′-act-
gactctgaggacttgcag–3′, and reverse: 5′-ggtgctgtcagtccaag-
ttc–3′; and for PP2Cb, forward: 5′-gggaagtcgagata-
acatgag-3′, and reverse: 5′-ccccatcactttctctatgtg-3′. An-
nealing temperature was 55C.
The absence of the SLC3A1 gene is compatible with
the early age at onset of renal calculi in all our patients;
in contrast, in a large series of cystinuric patients, only
25% reported their first stone during the first decade of
life (Stephens 1989). However, the concomitant occur-
rence of dysmorphism, neonatal seizures, hypotonia, and
Figure 3 a, Schematic representation of the deleted region. Upper part, The published sequence of the clones complementary to the sequence reported here. Lower part, Details of the clones.
The genes contained in the region are indicated by horizontal lines above them. Alignment of each exon was performed by means of the BLAST program of the genomic sequence to the nr database.
The 10 exons of the SLC3A1 (gray squares) have been published elsewhere. The genomic organization of the PP2Cb and KIAA0436 exons (black squares and squares marked with horizontal lines,
respectively) was derived from comparison of the mRNA sequence with the genomic sequence. The numbers of the first and last exons of these genes are indicated below the ruler line. Note that
exon 10 of SLC3A1 and exon 14 of KIAA0436 overlap; this overlap is in the 3′ untranslated regions of both genes. ESTs are represented by white squares. A hatched square between exons 4 and
5 of the PP2Cb gene represents a clone, AL11753, associated with a UniGene cluster that demonstrates no open reading frame. A pseudoribosomal gene in the interval between SLC3A1 and PP2Cb
is shown by a gray square, and “w Ribosomal” appears below it. The positions of the primers used for the definition of the deletion (primers a and b) and for the detection of the wild-type allele
(primer c) are marked by arrowheads. Light vertical lines represent the positions of STSs that were not amplified in the affected children. Bold vertical lines represent the positions of STSs that were
amplified in the affected children. The numbers on the ruler line are the original numbers in the published sequence of the clones (as appearing in May 1, 2001). The numbers at the ends of clone
RP11-24I5 that overlap the numbers of the overlapping clones are indicated. b, The sequence at the joining of the deletion ends. The PCR product derived from patient’s DNA with primers a and
b (as indicated in a) was subjected to sequencing. The regions contained in the adjacent clones RP11-194L1 and RP11-559M23 are represented by the upper lines. The four bases TTCC could be
derived from either clone, as they are present in both.
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severe somatic growth and psychomotor retardation is
not explained by the deletion of the SLC3A1 gene (Gold
et al. 1977). These features could be attributed to the
MRC defect identified in the muscle biopsy specimens
of three of the patients. Hypotonia, developmental delay,
and lactic acidemia are well-recognized signs of MRC
disorders. The findings of ragged red fibers in the muscle
biopsy specimen of one patient, the reduced activity of
the mitochondrial encoded enzymatic complexes in two
other patients, and the finding of mtDNA depletion in
the only patient whose muscle DNA was available for
analysis are all consistent with MRC disease.
mtDNA depletion is a heterogeneous group of auto-
somal disorders presenting in infancy, either with mul-
tisystem, fatal disease or isolated liver failure or with a
devastating myopathy simulating Duchenne muscular
dystrophy (Vu et al. 1998). The underlying pathology
may involve a component of the mtDNA replication
machinery that is encoded by an as-yet-unidentified gene
within the deleted region.
At present, we are unable to exclude the potential
contribution of the other genes, within the deleted re-
gion, to the phenotype of our patients. The protein ser-
ine/threonine phosphatase PP2Cb is widely expressed
but is most abundant in heart and skeletal muscle (Mar-
ley et al. 1998), and thus its absence may be the cause
of the muscle hypotonia. This phosphatase has two al-
ternative splicing variants at its 3′ end (see GenBank
accession numbers), and their tissue distribution and
functions are unknown. The cyclin-dependent kinases
Cdk2 and Cdk6 were reported to be the substrates of
one isoform, PP2Cb2, but not substrates of the other
PP2Cb isoform (Cheng et al. 2000). Thus the PP2Cb
gene with its different isoforms and ubiquitous tissue
distribution may have pleiotrophic effects that could
contribute to the patients’ phenotype. KIAA0436 rep-
resents a clone with weak homology to proteinase II
(Ishikawa et al. 1997). It is ubiquitously expressed, and
its function awaits further study.
Analyses using the programs Prediction of Protein Lo-
calization Sites (PSORT) and Prediction of Mitochon-
drial Targeting Sequences (MitoProt) indicate that nei-
ther KIAA0436 nor PP2Cb has a signal or mito-
chondrial targeting peptide.
Thus we have delineated a new syndrome caused by
a homozygous deletion of 179,311 bp on chromosome
2p16 and have identified part of the genes contained in
this region. In contrast to most deletion syndromes,
transmitted as dominant traits, the 2p16 deletion is re-
cessively inherited, implying that only half the product
of all genes within the deletion is sufficient for normal
life as observed in the parents and siblings of our pa-
tients. Further studies of these genes will contribute to
the understanding of their function and their relation to
the disease phenotype. Because the product of one of
these genes, at present probably represented only as an
EST, likely participates in the synthesis of the mito-
chondrial encoded protein, we suggest that families with
similar combinations of enzymatic defects should be in-
vestigated for linkage to this chromosomal region.
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